KRAS Mutation in Serous Borderline Tumor of the Testis: Report of a Case and Review of the Literature

  • Bouri S
  • Noël J
  • Catteau X
  • et al.
N/ACitations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Ovarian-like epithelial tumors of the testis, including serous borderline tumors, are rare entities. We report the case of a 60-year-old man with a left intratesticular mass who had a radical orchidectomy. Histologically, the tumor was identical to the ovarian counterpart showing a well-delineated cystic lesion characterized by intraluminal papillae. The papillae are lined by atypical cuboidal or ciliated cells and are associated with psammoma bodies. The tumor cells express cytokeratin 7 (CK7), cytokeratin 5-6 (CK5-6), cancer antigen 125 (CA125), estrogen (ER), progesterone (PR), Wilm’s tumor gene (WT1), paired box gene 8 (PAX8), Ber-EP4, and epithelial membrane antigen (EMA). The diagnosis of a serous borderline tumor of the testis was proposed. Mutation testing using next-generation sequencing showed a Q61K KRAS gene mutation. To the best of our knowledge, this is the second case report of a serous borderline tumor of the testis with a Q61K KRAS gene mutation.

Cite

CITATION STYLE

APA

Bouri, S., Noël, J.-C., Catteau, X., Al Hajj Obeid, W., Svistakov, I., Roumeguère, T., … Rorive, S. (2020). KRAS Mutation in Serous Borderline Tumor of the Testis: Report of a Case and Review of the Literature. Case Reports in Urology, 2020, 1–4. https://doi.org/10.1155/2020/5419707

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free